A new AI tool, BIOPREVENT, predicts serious post-transplant complications months before symptoms appear using blood biomarkers and clinical data.
Key Details
- 1BIOPREVENT was developed by MUSC Hollings Cancer Center and validated with data from 1,310 transplant recipients.
- 2The tool outperformed standard clinical models in predicting chronic graft-versus-host disease (GVHD) and transplant-related death.
- 3BIOPREVENT uses seven immune protein biomarkers and nine clinical factors to assess risk.
- 4Predictions were validated in an independent patient cohort, showing reliable risk stratification up to 18 months post-transplant.
- 5A free, web-based application is available for clinicians to use the tool for research and risk assessment.
Why It Matters
Early identification of high-risk transplant patients can enable closer monitoring and potential intervention before severe complications arise, representing a significant advance in personalized medicine using AI and biomarker data. This AI tool sets a precedent for broader use of machine learning models to improve outcomes in complex medical scenarios requiring longitudinal risk prediction.
Source
EurekAlert
Related News
•EurekAlert
AI Predicts Risks for Outpatient Stem Cell Therapy in Myeloma
Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.
•EurekAlert
USC Unveils Joint Biomedical Engineering Department Bridging Medicine, Engineering, and Imaging
USC's medical and engineering schools launch a joint biomedical engineering department to accelerate interdisciplinary research and innovation, including imaging and AI.
•EurekAlert
AI-Enhanced CT Heart Fat Measurement Boosts Cardiovascular Risk Prediction
AI-derived measurement of heart fat from CT scans significantly improves long-term cardiovascular disease risk prediction.